Literature DB >> 23706948

Incidence and progression of geographic atrophy: observations from a population-based cohort.

Nichole Joachim1, Paul Mitchell, Annette Kifley, Elena Rochtchina, Thomas Hong, Jie Jin Wang.   

Abstract

PURPOSE: To examine early age-related macular degeneration (AMD) lesion characteristics and risk factors associated with the long-term development and progression of geographic atrophy (GA).
DESIGN: Population-based cohort. PARTICIPANTS: Of 3654 participants aged ≥49 years in the Blue Mountains Eye Study, 75.8%, 76.7%, and 56.1% of survivors attended the 5-, 10-, and 15-year follow-up examinations, respectively.
METHODS: Retinal photographs were taken at each visit. Incident GA was confirmed using a side-by-side grading method. Computer planimetry was used to measure the area involved by GA. Fast and slow/normal progression rates were defined as GA area enlargement by ≥2 and <2 mm(2)/year, respectively. Incident GA was estimated using the Kaplan-Meier product-limit method. Early AMD lesion characteristics were assessed for association with GA incidence using eye-specific data and generalized estimating equation models adjusting for age, current smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes, genotyped or imputed using genome-wide scan data. MAIN OUTCOME MEASURES: Incidence and progression of GA.
RESULTS: By excluding 41 subjects with GA at baseline, of 2503 participants at risk of GA, incident pure GA (without coexisting neovascular AMD lesions) was confirmed in 57 participants, with a 15-year incidence of 3.6%. Baseline early AMD lesion characteristics associated with GA incidence included drusen type (soft indistinct: odds ratio [OR], 59.0; 95% confidence interval [CI], 20.4-171.0; reticular drusen: OR, 13.9; 95% CI, 4.0-47.6); drusen location within a 500-μm radius of the fovea (OR, 15.1; 95% CI, 7.4-30.8); drusen area greater than 375 μm in diameter (OR, 10.1; 95% CI, 4.0-25.6); presence of retinal pigment epithelial depigmentation (OR, 9.0; 95% CI, 4.1-19.8); or hyperpigmentation (OR, 12.0; 95% CI, 6.1-23.5), referenced to subjects with no or hard drusen only. Fast progression was more frequent among current smokers at baseline, subjects with the CFH or ARMS2 risk genotypes, and pseudophakic eyes.
CONCLUSIONS: Early AMD lesion characteristics (type, location, area involved) were strongly associated with higher long-term risk of developing GA independent of age, smoking, and AMD genetic susceptibility from the CFH or ARMS2 genes. Known AMD risk factors also were more frequently present among quickly progressing GA cases. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706948     DOI: 10.1016/j.ophtha.2013.03.029

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  Comparison of retinal image evaluation techniques in novice clinicians.

Authors:  Christopher M Putnam; Alex Permann; Carl J Bassi
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-22

2.  Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin
Journal:  Ophthalmology       Date:  2016-10-27       Impact factor: 12.079

3.  Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.

Authors:  Tiarnan D Keenan; Elvira Agrón; Amitha Domalpally; Traci E Clemons; Freekje van Asten; Wai T Wong; Ronald G Danis; SriniVas Sadda; Philip J Rosenfeld; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frederick L Ferris; Emily Y Chew
Journal:  Ophthalmology       Date:  2018-07-27       Impact factor: 12.079

4.  Progression of Unifocal versus Multifocal Geographic Atrophy in Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.

Authors:  Liangbo L Shen; Mengyuan Sun; Holly K Grossetta Nardini; Lucian V Del Priore
Journal:  Ophthalmol Retina       Date:  2020-04-04

Review 5.  Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review.

Authors:  Patrick Kaszubski; Tal Ben Ami; Celine Saade; R Theodore Smith
Journal:  Ophthalmic Res       Date:  2016-02-13       Impact factor: 2.892

6.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Gui-Shuang Ying; Maureen G Maguire; Ebenezer Daniel; Daniel F Martin
Journal:  Ophthalmology       Date:  2014-12-24       Impact factor: 12.079

Review 7.  Imaging and artificial intelligence for progression of age-related macular degeneration.

Authors:  Kathleen Romond; Minhaj Alam; Sasha Kravets; Luis de Sisternes; Theodore Leng; Jennifer I Lim; Daniel Rubin; Joelle A Hallak
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-18

8.  Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.

Authors:  Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

9.  Characteristics of Geographic atrophy in an elderly UK population-The Bridlington Eye Assessment Project (BEAP): a cross-sectional study (2002-2006).

Authors:  Craig Wilde; Ali Poostchi; Jonathan G Hillman; Hamish K MacNab; Stephen A Vernon; Winfried M Amoaku
Journal:  Eye (Lond)       Date:  2020-08-31       Impact factor: 4.456

10.  Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.

Authors:  Christopher Schütze; Manuela Wedl; Bernhard Baumann; Michael Pircher; Christoph K Hitzenberger; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2015-03-10       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.